Editor: Willem van Leeuwen
Immune response to leishmania: paradox rather than paradigm
Article first published online: 22 AUG 2007
FEMS Immunology & Medical Microbiology
Volume 51, Issue 2, pages 229–242, November 2007
How to Cite
Tripathi, P., Singh, V. and Naik, S. (2007), Immune response to leishmania: paradox rather than paradigm. FEMS Immunology & Medical Microbiology, 51: 229–242. doi: 10.1111/j.1574-695X.2007.00311.x
- Issue published online: 22 AUG 2007
- Article first published online: 22 AUG 2007
- Received 23 April 2007; revised 26 June 2007; accepted 26 June 2007.First published online 22 August 2007.
- T-cell response;
- dendritic cells;
- visceral leishmaniasis;
- cutanaeous leishmaniasis
The leishmaniases are a group of diseases caused by protozoan parasites of the genus Leishmania. Various Leishmania species can cause human infection, producing a spectrum of clinical manifestations. It is estimated that 350 million people are at risk, with a global yearly incidence of 1–1.5 million for cutaneous and 500 000 for visceral leishmaniasis (VL). VL is a major cause of morbidity and mortality in East Africa and the Indian subcontinent. Coinfection with HIV enhances the risk of the disease. The only control measure currently available in India is case detection and treatment with antimonial drugs, which are expensive, not always available and cannot be self-administered. Newer drugs like oral miltefosine have not become widely available. Vector and reservoir control is difficult due to the elusive nature of the vector and the diversity of the animal reservoir. A detailed knowledge of immune response to the parasite would help in designing prophylactic and therapeutic strategies against this infection.